<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646564</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2493</org_study_id>
    <nct_id>NCT04646564</nct_id>
  </id_info>
  <brief_title>Radiotherapy for Extracranial Oligometastatic Breast Cancer</brief_title>
  <official_title>Systemic Therapy With or Without Local Radiotherapy for Extracranial Oligometastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Union Hospital, Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Hospital of Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      More and more evidence suggests that local radiotherapy can improve the outcomes for patients&#xD;
      with oligometastatic disease. The purpose of this study is to assess the impact of&#xD;
      radiotherapy, compared with standard systemic therapy alone, on survival, local control and&#xD;
      toxicities in patients with extracranial oligometastatic breast cancer. Eligible patients are&#xD;
      randomized in a 1:2 ratio between the control arm (standard systemic therapy), and the WLRT&#xD;
      arm (standard systemic therapy + radiotherapy). Randomization will be stratified by three&#xD;
      factors: visceral metastasis (yes vs.no), number of metastases(≤2 vs. &gt;2), hormone&#xD;
      receptor(positive vs. negative). SBRT technique is preferred. During and after radiotherapy,&#xD;
      the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomization to disease progression at any site or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of tumor control within RT fields during follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of acute and late toxicities from treatment graded according to radiation therapy oncology group (RTOG) radiation injury criteria and National Cancer Institute CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured by the Functional Assessment of Cancer Therapy- General (FACT-G)</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of quality of life scores by FACT-G</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational exploration</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of circulating tumor cells (CTCs), ctDNA, as prognostic and predictive markers of survival, and for early detection of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of acceptable SBRT completion</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients who completed SBRT with acceptable dose prescriptions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiotherapy + standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.</description>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_label>study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy + standard of care</intervention_name>
    <description>Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.&#xD;
Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.</description>
    <arm_group_label>study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years old&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  Metachronous extracranial oligometastatic diseases which occurred after 3 months after&#xD;
             radical surgery, and diagnosed by pathology or imaging. Biopsy of metastasis is&#xD;
             preferred.&#xD;
&#xD;
          -  Total number of metastases 1-5 , the maximum diameter of metastases ≤5 cm and at least&#xD;
             one lesion could be evaluated by RECIST1.1.&#xD;
&#xD;
          -  Have received or plan to receive systemic therapy.&#xD;
&#xD;
          -  All lesions could be safely treated by radiotherapy.&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
          -  Have adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have simultaneous locoregional recurrences.&#xD;
&#xD;
          -  Have metastases in the central nervous system.&#xD;
&#xD;
          -  have indications for palliative radiotherapy to reduce symptoms, such as pain,&#xD;
             bleeding, obstruction, and pending fractures caused by the tumor.&#xD;
&#xD;
          -  Have moderate/severe liver dysfunction (Child Pugh B or C) from liver metastases, .&#xD;
&#xD;
          -  Malignant pleural effusion&#xD;
&#xD;
          -  Unable to tolerate radiotherapy due to serious comorbidity&#xD;
&#xD;
          -  Have received prior radiotherapy for target area&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu-lian Wang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shu-lian Wang, M.D</last_name>
    <phone>8610-87788803</phone>
    <email>wsl20040118@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shu lian Wang</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>breast neoplasm</keyword>
  <keyword>oligometastases</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>stereotactic ablative radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

